Risedronate Inhibition of Matrix Metalloproteinase-2 Expression in Osteosarcoma Cell Line  

作　　者：Kim Yang KYUNG Sung Taek JUNG Taek Rim YOON 

机构地区：[1]The Brain Korea 21 Project Center for Biomedical Human Resources [2]Department of Orthopaedic Surgery Chonnam National University Medical School

出　　处：《中国肺癌杂志》2009年第6期664-665,共2页Chinese Journal of Lung Cancer

摘　　要：Background and objective Osteosarcoma is a high-malignant bone tumor and is the most frequent malignant bone tumor in children and adolescents. Significant proportions of theBackground and objective Osteosarcoma is a high-malignant bone tumor and is the most frequent malignant bone tumor in children and adolescents. Significant proportions of the patient eventually develop pulmonary metastases and succumb to their disease even after conventional multi-agent chemotherapy and surgical excision. Several solid tumors display enhanced expression of matrix metalloproteinases （MMPs）, and recently MMP- inhibitors have entered clinical trials. Bisphosphonate （BPs） have a profound effect on bone resorption and are widely used in treatment of osteoclast-mediated bone diseases and have been known to inhibit tumor growth and metastasis in some tumors such as breast cancer, renal cell carcinoma, and prostate cancer. The purpose of this study was to investigate the effect of the bisphosphonate on osteosarcoma cell invasion.

关 键 词：肺癌 恶性肿瘤 炎症 Β-七叶皂甙钠 

分 类 号：R738.1[医药卫生—肿瘤]